Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study.
Atul A DeodharJerzy SupronikAlan KivitzGuillermo ValenzuelaKaren KapurSusanne RohrerEva DokoupilovaHanno B RichardsKarel PavelkaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
IV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks. The safety profile was consistent with that in previous reports on subcutaneous secukinumab.
Keyphrases
- phase iii
- ankylosing spondylitis
- placebo controlled
- double blind
- open label
- phase ii
- clinical trial
- disease activity
- rheumatoid arthritis
- study protocol
- phase ii study
- randomized controlled trial
- high dose
- squamous cell carcinoma
- gestational age
- low dose
- emergency department
- radiation therapy
- preterm birth
- rectal cancer